Rapport Therapeutics (RAPP) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $29.57, +4.38% vs the prior close of $28.33.
- Volume 334.90K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RAPP jumps 4.4% to $29.57. Closed at $29.57, +4.38% vs the prior close of $28.33. Day range $28.67–$30.48, opened at $29.12.
RAPP daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RAPP jumps 4.4% to $29.57
- Closed at $29.57, +4.38% vs the prior close of $28.33. Day range $28.67–$30.48, opened at $29.12.
- Volume was 334.90K shares, 0.9x its 50-day average of 362.36K.
- Price is -28.6% vs its 50-day average ($41.44) and -17.3% vs its 200-day average ($35.78).
- 52-week range $23.75–$52.93; today's close sits at 20% of that range, 44.1% below the 52-week high.
Oct 14, 2026 — RAPP dips 2.3% to $28.33, a 6-month low, 3 down days in a row
- Closed at $28.33, -2.28% vs the prior close of $28.99. Day range $28.10–$29.31, opened at $28.71.
- Volume was 304.00K shares, 0.8x its 50-day average of 364.24K.
- Price is -32.1% vs its 50-day average ($41.70) and -20.8% vs its 200-day average ($35.78).
- 52-week range $23.75–$52.93; today's close sits at 16% of that range, 46.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — RAPP slides 3.8% to $28.99, a 6-month low
- Closed at $28.99, -3.85% vs the prior close of $30.15. Day range $28.68–$30.01, opened at $30.00.
- Volume was 310.00K shares, 0.9x its 50-day average of 364.34K.
- Price is -30.9% vs its 50-day average ($41.97) and -19.0% vs its 200-day average ($35.79).
- 52-week range $23.75–$52.93; today's close sits at 18% of that range, 45.2% below the 52-week high.
Oct 12, 2026 — RAPP dips 1.6% to $30.15
- Closed at $30.15, -1.63% vs the prior close of $30.65. Day range $30.00–$30.99, opened at $30.65.
- Volume was 127.10K shares, 0.3x its 50-day average of 366.62K — lighter than usual.
- Price is -28.6% vs its 50-day average ($42.21) and -15.8% vs its 200-day average ($35.80).
- 52-week range $23.75–$52.93; today's close sits at 22% of that range, 43.0% below the 52-week high.
Oct 9, 2026 — RAPP rises 2.7% to $30.65
- Closed at $30.65, +2.68% vs the prior close of $29.85. Day range $29.50–$31.20, opened at $29.73.
- Volume was 247.90K shares, 0.7x its 50-day average of 366.00K.
- Price is -27.8% vs its 50-day average ($42.43) and -14.4% vs its 200-day average ($35.80).
- 52-week range $23.75–$52.93; today's close sits at 24% of that range, 42.1% below the 52-week high.
Oct 8, 2026 — RAPP slides 3.3% to $29.85, a 6-month low, 3 down days in a row
- Closed at $29.85, -3.27% vs the prior close of $30.86. Day range $29.45–$30.62, opened at $30.62.
- Volume was 236.80K shares, 0.6x its 50-day average of 367.72K.
- Price is -30.0% vs its 50-day average ($42.67) and -16.6% vs its 200-day average ($35.81).
- 52-week range $23.75–$52.93; today's close sits at 21% of that range, 43.6% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — RAPP dips 0.9% to $30.86, a 6-month low
- Closed at $30.86, -0.93% vs the prior close of $31.15. Day range $30.45–$31.35, opened at $30.81.
- Volume was 315.00K shares, 0.9x its 50-day average of 368.50K.
- Price is -28.1% vs its 50-day average ($42.89) and -13.8% vs its 200-day average ($35.81).
- 52-week range $23.75–$52.93; today's close sits at 24% of that range, 41.7% below the 52-week high.
Oct 6, 2026 — RAPP slides 3.2% to $31.15, a 6-month low
- Closed at $31.15, -3.23% vs the prior close of $32.19. Day range $30.01–$34.00, opened at $32.92.
- Volume was 235.60K shares, 0.6x its 50-day average of 370.04K.
- Price is -27.7% vs its 50-day average ($43.11) and -13.0% vs its 200-day average ($35.81).
- 52-week range $23.75–$52.93; today's close sits at 25% of that range, 41.1% below the 52-week high.
Oct 5, 2026 — RAPP ends flat (+0.1%) to $32.19
- Closed at $32.19, +0.06% vs the prior close of $32.17. Day range $31.53–$32.71, opened at $32.22.
- Volume was 198.50K shares, 0.5x its 50-day average of 371.46K — lighter than usual.
- Price is -25.7% vs its 50-day average ($43.33) and -10.1% vs its 200-day average ($35.79).
- 52-week range $23.75–$52.93; today's close sits at 29% of that range, 39.2% below the 52-week high.
Oct 2, 2026 — RAPP dips 2.0% to $32.17, a 6-month low
- Closed at $32.17, -2.01% vs the prior close of $32.83. Day range $31.77–$34.48, opened at $33.33.
- Volume was 276.30K shares, 0.7x its 50-day average of 370.51K.
- Price is -26.1% vs its 50-day average ($43.50) and -10.1% vs its 200-day average ($35.79).
- 52-week range $23.75–$52.93; today's close sits at 29% of that range, 39.2% below the 52-week high.
RAPP latest news & SEC filings
Every SEC filing by or about RAPP in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ceesay Abraham sold 3,375 shares at $32.03 (≈$108.11K) on Oct 6, 2026; now holds 453,392
- Ceesay Abraham sold 1,147 shares at $30.66 (≈$35.17K) on Oct 7, 2026; now holds 452,245
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gault Cheryl sold 7,925 shares at $33.04 (≈$261.81K) on Sep 30, 2026; now holds 141,989
- Gault Cheryl sold 2,075 shares at $33.76 (≈$70.04K) on Sep 30, 2026; now holds 139,914
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ceesay Abraham sold 1,952 shares at $39.05 (≈$76.23K) on Sep 23, 2026; now holds 457,025
- Ceesay Abraham sold 215 shares at $39.86 (≈$8.57K) on Sep 23, 2026; now holds 456,810
- Ceesay Abraham sold 43 shares at $41.05 (≈$1.77K) on Sep 23, 2026; now holds 456,767
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ceesay Abraham sold 7,141 shares at $45.56 (≈$325.34K) on Sep 8, 2026
- Ceesay Abraham sold 1,069 shares at $46.01 (≈$49.18K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$56.62M (prior year -$26.73M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.19 (prior year -$0.75) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade RAPP
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 10, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.00% (largest 17.7%).
- Liquidity: about 474.62K shares (≈$14.03M) trade per day on average.
- 52-week position: $29.57 vs a range of $23.75–$52.93 (20% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Abraham Ceesay sold 43 shares on Sep 23, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 10, 2026.
- Share count: 47.98M shares outstanding (Aug 3, 2026), +31.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RAPP market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 29.12 | 30.48 | 28.67 | 29.57 | 334.90K |
| Oct 14, 2026 | 28.71 | 29.31 | 28.10 | 28.33 | 304.00K |
| Oct 13, 2026 | 30.00 | 30.01 | 28.68 | 28.99 | 310.00K |
| Oct 12, 2026 | 30.65 | 30.99 | 30.00 | 30.15 | 127.10K |
| Oct 9, 2026 | 29.73 | 31.20 | 29.50 | 30.65 | 247.90K |
| Oct 8, 2026 | 30.62 | 30.62 | 29.45 | 29.85 | 236.80K |
| Oct 7, 2026 | 30.81 | 31.35 | 30.45 | 30.86 | 315.00K |
| Oct 6, 2026 | 32.92 | 34.00 | 30.01 | 31.15 | 235.60K |
| Oct 5, 2026 | 32.22 | 32.71 | 31.53 | 32.19 | 198.50K |
| Oct 2, 2026 | 33.33 | 34.48 | 31.77 | 32.17 | 276.30K |
| Oct 1, 2026 | 33.52 | 34.31 | 32.80 | 32.83 | 326.80K |
| Sep 30, 2026 | 33.17 | 34.05 | 32.62 | 33.60 | 581.70K |
| Sep 29, 2026 | 33.25 | 33.66 | 32.12 | 33.02 | 626.10K |
| Sep 28, 2026 | 33.48 | 33.99 | 32.36 | 33.44 | 552.30K |
| Sep 25, 2026 | 33.80 | 34.89 | 33.05 | 33.91 | 711.80K |
| Sep 24, 2026 | 34.15 | 34.21 | 31.58 | 33.83 | 848.50K |
| Sep 23, 2026 | 41.01 | 41.47 | 33.38 | 34.13 | 743.70K |
| Sep 22, 2026 | 39.97 | 41.55 | 37.94 | 41.47 | 900.20K |
| Sep 21, 2026 | 40.70 | 42.18 | 39.11 | 39.66 | 617.00K |
| Sep 18, 2026 | 41.89 | 43.00 | 40.28 | 40.45 | 998.10K |
About Rapport Therapeutics
Rapport Therapeutics (RAPP) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2012593.
RAPP board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Abraham Ceesay | Chief Executive Officer | Sep 24, 2026 |
| James Healy | Director | Jun 10, 2026 |
| Reid M Huber | Director | Jun 10, 2026 |
| John Maraganore | Director | Jun 10, 2026 |
| Steven M Paul | Director | Jun 10, 2026 |
| Robert J Perez | Director | Jun 10, 2026 |
| Ramiro Sanchez | Director | Jun 10, 2026 |
| Paul M Silva | Director | Jun 10, 2026 |
| Wendy B. Young | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David Bredt | Chief Scientific Officer | Feb 19, 2026 |
| Abraham Ceesay | Chief Executive Officer | Sep 24, 2026 |
| Cheryl Gault | Chief Operating Officer | Jul 1, 2026 |
| Troy A. Ignelzi | Chief Financial Officer | Feb 4, 2026 |
| Jeffrey Sevigny | Chief Medical Officer | Feb 4, 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | Aug 26, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 23, 2026 | Abraham Ceesay | Sale | 43 | $41.05 |
| Sep 23, 2026 | Abraham Ceesay | Sale | 1,952 | $39.05 |
| Sep 23, 2026 | Abraham Ceesay | Sale | 215 | $39.86 |
| Sep 8, 2026 | Abraham Ceesay | Sale | 7,141 | $45.56 |
| Sep 8, 2026 | Abraham Ceesay | Sale | 1,069 | $46.01 |
| Aug 25, 2026 | Krishnaswamy Yeleswaram | Sale | 16,201 | $51.06 |
| Aug 25, 2026 | Krishnaswamy Yeleswaram | Sale | 20,799 | $50.31 |
| Aug 25, 2026 | Abraham Ceesay | Sale | 18,921 | $49.57 |
| Aug 24, 2026 | Krishnaswamy Yeleswaram | Sale | 13,160 | $50.00 |
| Aug 19, 2026 | Krishnaswamy Yeleswaram | Sale | 404 | $49.90 |
| Aug 11, 2026 | Abraham Ceesay | Sale | 3,664 | $46.90 |
| Aug 11, 2026 | Abraham Ceesay | Sale | 19,500 | $48.04 |
| Aug 11, 2026 | Abraham Ceesay | Sale | 5,794 | $48.62 |
| Aug 10, 2026 | Abraham Ceesay | Sale | 14,171 | $45.97 |
| Aug 10, 2026 | Abraham Ceesay | Sale | 8,370 | $46.75 |
RAPP financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-111.48M | -2.86 | $-87.47M |
| Dec 31, 2024 | — | $-78.31M | -3.78 | $-64.83M |
| Dec 31, 2023 | — | $-34.79M | -23.10 | $-27.18M |
Latest balance sheet: total assets $458.98M, total liabilities $36.06M, cash $63.61M (as of Jun 30, 2026).
RAPP earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $42.44 |
| May 7, 2026 | 8-K Item 2.02 (results) | $39.93 |
| Mar 10, 2026 | 8-K Item 2.02 (results) | $29.63 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $25.36 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $15.41 |
| May 8, 2025 | 8-K Item 2.02 (results) | $10.65 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $8.96 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $26.90 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RAPP
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.